Bladder cancer drug combo trial halted early
NCT ID NCT04601857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, futibatinib and pembrolizumab, in 43 people with advanced or metastatic bladder cancer who could not receive standard chemotherapy. The goal was to see if the combo could shrink tumors and to check its safety. The trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED AND METASTATIC UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALTHAIA, Xarxa Assistencial Universitària de Manresa
Manresa, Brcelona, 8243, Spain
-
Centre Georges-François Leclerc
Dijon, Côte d'Or, 21079, France
-
Centre Leon Berard - departement d'oncologie medicale
Lyon, Rhone, 69373, France
-
Centre Regional de Lutte Contre le Cancer de Lorraine
Vandœuvre-lès-Nancy, 54500, France
-
Comprehensive Care Centers of Nevada
Las Vegas, Nevada, 89148, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario HMN Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, 39008, Spain
-
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
-
Hospital Universitario Vall d'Hebrón
Barcelona, 8035, Spain
-
Hospital de La Santa Creu i Sant Pau
Barcelona, 8025, Spain
-
Hospital la Fe
Valencia, 46026, Spain
-
ICANS - Institut de cancérologie de Strasbourg Europe
Strasbourg, Bas-Rhin, 67200, France
-
Institut De Cancerologie Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli Calmettes - Hôpital de jour
Marseille, Bouches-du-Rhône, 13273, France
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.